Study for metastatic kidney cancer treatments combinations
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies people with advanced (metastatic) kidney cancer who are starting a specific set of first-line treatment combinations (including drugs like nivolumab, pembrolizumab, or avelumab, paired with targeted medicines). It may help improve how these treatment plans work for different types of kidney cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old
- Have kidney cancer confirmed under a microscope (clear cell or non-clear cell)
- Have metastatic (spread) kidney cancer confirmed by scan and/or biopsy
- Be starting one of the listed first-line treatment combinations
- Not have received a different immunotherapy combination than the ones listed for the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This Phase 2 trial studies whether combining axitinib and pembrolizumab can shrink and control metastatic or inoperable type 2 or mixed papillary kidney cancer. It may help by blocking cancer growth signals and boosting the immune system to attack the cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
Hear when a new Metastatic Renal Cell Carcinoma (mRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.